raising funds via bank of ny mellon, page-19

Look in all reality clinical trials are a very long way from being a cheap exercise. PhaseIII are the most time consuming, have the largest patient numbers, carried out over the longest duration & usually over multiple sites - they are also the most cash intensive leg.

Yes PRR have a little cash in the bank but it is nowhere near the required capital to carry through the remaining trials. While there may be the presumptions that common stock is being bought here & this will in effect become the stock then to trade on the NASDAQ, i think it is much more likely that a significant placement or capital raising will be undertaken in the near future to well fund the company into PhaseIII and in turn the entire issue of this stock will be what is then bundled into ADR's....

It just comes down to what price they raise the capital